- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
USFDA appoints Sean Keveney as Chief Counsel

Washington: The U.S. Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA) have announced that Sean Keveney has been appointed Chief Counsel at the FDA.
Keveney most recently served as Acting General Counsel of HHS, where he led the Department’s legal team in advancing key administration priorities and ensuring rigorous legal standards across public health programs.
“America is in a golden age of food and drug regulation,” said FDA Commissioner Dr. Marty Makary. “From modernizing the agency to address national priorities to phasing out the petroleum-based food dyes linked to behavior disorders in children, the FDA is accomplishing things under the Trump Administration that few previously thought possible. Sean Keveney’s appointment as our Chief Counsel reflects the talent and experience we have brought to FDA for the mission to Make America Healthy Again.”
As Acting General Counsel at HHS, Keveney led the Department’s work for the Trump Administration on one of the most successful discrimination crackdowns in American history. HHS found that Harvard University and Columbia University through their medical schools violated Title VI of the Civil Rights Act of 1964 and completed Title VI investigations of Brown University and Duke University. The Trump Administration subsequently reached settlements with Columbia and Brown, requiring Columbia to undergo three years of independent monitoring for compliance with federal law, and prohibiting Brown from performing gender reassignment surgeries on minors or prescribing puberty blockers or cross-sex hormones to them.
A career public servant with previous senior roles in the Department of Justice’s Civil Rights Division, Keveney clerked on the U.S. Court of Appeals for the Fifth Circuit for Judge William Garwood, an appointee of President Ronald Reagan. His leadership at HHS spanned major litigation, civil rights enforcement, and regulatory reform.
Robert Foster, the Department’s Principal Deputy General Counsel, will assume the role of Acting General Counsel of HHS. He will remain FDA Chief Counsel for Food, Research, and Drugs. Foster has deep experience in administrative law and public health litigation and has been a trusted advisor to Secretary Robert F. Kennedy, Jr. on matters ranging from vaccine regulation to bioethics.
President Trump earlier this year nominated Michael Stuart, a member of the West Virginia Senate and former United States Attorney for the Southern District of West Virginia, as General Counsel of HHS. The U.S. Senate Committee on Finance held his nomination hearing on July 31, 2025
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751